

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF NEW YORK**

LOUIS LASTRES, on behalf of himself and
all others similarly situated,

Plaintiff,

v.

RITE AID CORPORATION,

Defendant.

Case No. _____

JURY TRIAL DEMANDED

CLASS ACTION COMPLAINT

Plaintiff Louis Lastres, by and through his attorneys, brings this class action on behalf of himself and similarly-situated others who purchased health supplements containing glucosamine and/or chondroitin manufactured and marketed Rite Aid, Corp. (“Rite Aid” or “Defendant”) and sold under its own house-brand label, and states as follows:

INTRODUCTION AND NATURE OF ACTION

1. Rite Aid is a national retailer/pharmacy with approximately 4,600 stores in 31 states and the District of Columbia.
2. Rite Aid sells its name-brand products in its stores and online via its website. Rite Aid operates stores in the State of New York and, in addition, ships a significant amount of products to residents of New York.
3. In addition to brand-name products, Rite Aid manufactures and sells a house-brand line of products under the “Rite Aid” label, including joint health dietary supplements

(collectively referred to as the “Supplements”).¹ According to the labels on these products, the purported active ingredients are, among others, glucosamine sulfate, chondroitin sulfate.

4. In its uniform, nationwide marketing of the Supplements, Rite Aid promises that they “help rebuild cartilage & lubricate joints”.

5. While Rite Aid’s claims regarding the improved joint function associated with the Supplements are directed at anyone seeking to alleviate joint pain or stiffness, they are particularly directed at people suffering from osteoarthritis. Indeed, the most common symptoms of osteoarthritis include joint pain and stiffness—the very symptoms the Supplements claim to remedy.²

6. Despite Rite Aid’s claims regarding the benefits and efficacy of glucosamine and chondroitin, however, the bulk, if not all, of the reliable and published scientific studies demonstrate that Rite Aid’s claims are false and misleading.

7. Most damning to Rite Aid’s claims is a large scale study sponsored and conducted by the National Institute of Health (“NIH”) called the Glucosamine/chondroitin Arthritis Intervention Trial (“GAIT”), which concluded, in a report published in the New England Journal of Medicine, that “[glucosamine and chondroitin], alone or in combination, was not efficacious. . .” Clegg, D., et al., *Glucosamine, Chondroitin Sulfate, and the Two in Combination for Painful Knee Osteoarthritis*, 354 New England J. of Med. 795, 806 (2006).³

¹ The Supplements include, but are not necessarily limited to 1) Rite Aid Glucosamine/Chondroitin; 2) Rite Aid Natural Glucosamine/Chondroitin; 3) Rite Aid Glucosamine Chondroitin Advanced Complex; 4) Rite Aid Glucosamine Chondroitin, Triple Strength + MSM; 5) Rite Aid Glucosamine Chondroitin + MSM; 6) Rite Aid Glucosamine Chondroitin Advanced Complex with HA; 7) Rite Aid Glucosamine Sulfate

² See <http://www.webmd.com/osteoarthritis/guide/osteoarthritis-basics> (noting that the symptoms of osteoarthritis include “joint aching and soreness,” “pain,” and “stiffness”).

³ The GAIT Study was conducted by the National Center for Complementary and Alternative Medicine, which is, according to its website “is the Federal Government’s lead agency for scientific research on the diverse medical and health care systems, practices, and products that are not generally considered part of conventional medicine.”

8. Thus, in addition to affirmatively misrepresenting the joint health benefits of the Supplements, Rite Aid's failure to disclose facts regarding this and other similar studies also constitutes deception by omission or concealment. As a result, Defendant's joint health benefit representations and omissions are false, misleading and reasonably likely to deceive the public.

9. The misleading representations and omissions by Rite Aid are conveyed to the consuming public uniformly and through a variety of media including its website and online promotional materials and the labeling/packaging of the Supplements themselves. In short, Defendant's uniform advertising and marketing virtually ensure that the only reason a consumer would purchase the Supplements is to obtain the advertised joint health benefits—benefits that Rite Aid knows the Supplements fail to provide.

10. As a result of Defendant's deceptive joint health benefit representations, consumers – including Plaintiff and members of the proposed Class – have purchased products that do not perform as advertised.

11. Plaintiff brings this action on behalf of himself and all other similarly situated consumers to halt the dissemination of this false and misleading advertising message, correct the false and misleading perception it has created in the minds of consumers, and obtain redress for those who have purchased the Supplements based on violations of New York deceptive acts/false advertising laws and breach of express warranties. Plaintiff seeks injunctive and monetary relief for all consumers who purchased the Supplements.

JURISDICTION AND VENUE

12. This Court has original jurisdiction pursuant to 28 U.S.C. § 1332(d)(2). Plaintiff Lastres is a citizen of New York, and Defendant Rite Aid is a citizen of Delaware (Defendant's state of incorporation) and Pennsylvania (where Defendant's principal place of business is located). The matter in controversy, exclusive of interest and costs, exceeds the sum or value of \$5,000,000 and is a class action in which there are in excess of 100 class members and many members of the Class (including, specifically, Plaintiff Lastres) are citizens of a state different from Defendant.

13. This Court has jurisdiction because Defendant conducts business in the State of New York by regularly selling its products to New York residents in both its stores and via its website.

14. Venue is proper in this Court pursuant to 28 U.S.C. §§ 1391(a) and (b) because Defendant is a resident of this state and judicial district.

PARTIES

15. Plaintiff, Louis Lastres, resides in Staten Island; he is a citizen of New York. Plaintiff Lastres suffers from joint discomfort. During the class period, Plaintiff Lastres purchased certain of the Supplements at Rite Aid stores in New York City in reliance on Rite Aid's claims that the Supplements would "help rebuild cartilage & lubricate joints." If Plaintiff Lastres was aware that Rite Aid had both misrepresented the benefits of the Supplements and, in addition, concealed its knowledge of studies demonstrating the lack of efficacy of those products, he would not have purchased the Supplements. Plaintiff Lastres used the Supplements as directed and did not receive any of the promised benefits. As a result, Plaintiff Lastres suffered an injury in fact and lost the money associated with his purchase.

16. Defendant Rite Aid is a Delaware corporation with its principal place of business at 30 Hunter Lane; Camp Hill, Pennsylvania 17011. At all relevant times, Rite Aid has advertised, marketed, provided, offered, distributed, and/or sold the Supplements throughout the United States including to individuals in New York such as Plaintiff and the Class.

ALLEGATIONS

The False and Misleading Marketing Claims

17. This lawsuit concerns the products marketed and sold by Rite Aid including, but not limited to: 1) Rite Aid Glucosamine/Chondroitin; 2) Rite Aid Natural Glucosamine/Chondroitin; 3) Rite Aid Glucosamine Chondroitin Advanced Complex; 4) Rite Aid Glucosamine Chondroitin, Triple Strength + MSM; 5) Rite Aid Glucosamine Chondroitin + MSM; 6) Rite Aid Glucosamine Chondroitin Advanced Complex with HA; 7) Rite Aid Glucosamine Sulfate (all listed and unlisted products referred to herein, collectively, as the “Supplements”).⁴ These products frequently come in a variety of dosages and sizes, so the total number of relevant products sold by Rite Aid may exceed those listed above.

18. Marketed as joint health dietary supplements, the Supplements purportedly relieve joint pain through the combination of their ingredients.

19. According to Defendant’s website and to the packaging/label, the Supplements “help rebuild cartilage & lubricate joints.”

Multiple Clinical Studies Demonstrate That the Supplements Are Ineffective

20. Rite Aid’s representations about the efficacy of the ingredients in the Supplements products are totally contradicted by all credible scientific evidence. Indeed, since 2004, multiple clinical studies have found that glucosamine and chondroitin, alone or in combination, are not effective in providing the represented joint health benefits.

⁴ Plaintiff reserves the right to include other products upon completion of discovery.

21. In 2004, one study concluded that glucosamine was no more effective than a placebo in treating the symptoms of knee osteoarthritis. McAlindon et al., *Effectiveness of Glucosamine For Symptoms of Knee Osteoarthritis: Results From an Internet-Based Randomized Double-Blind Controlled Trial*, 117(9) Am. J. Med. 649 (Nov. 2004).

22. Indeed, as early as 2004, other clinical studies indicated a significant “placebo” effect when patients consumed products they were told had the potential to cure joint aches and pains. For example, one 2004 study involved a six-month study of the effects of glucosamine compared with placebo and concluded that there was no difference in primary or secondary outcomes between the two. Cibere et al., *Randomized, Double-Blind, Placebo-Controlled Glucosamine Discontinuation Trial In Knee Osteoarthritis*, 51(5) Arthritis Care & Research 738-45 (Oct. 15, 2004). The authors concluded that the study provided *no evidence* of symptomatic benefit from continued use of glucosamine and that perceived benefits were, in fact, due to the placebo effect and not any real benefit provided by glucosamine. *Id.*

23. In 2006, the first GAIT study concluded that “[t]he analysis of the primary outcome measure did not show that either supplement, alone or in combination, was efficacious.” 2006 GAIT Study at 806. Subsequent GAIT studies in 2008 and 2010 reported that glucosamine and chondroitin did not rebuild cartilage⁵ and were otherwise ineffective – even in patients with moderate to severe knee pain for which the 2006 GAIT study reported results were inconclusive. See Sawitzke, A.D., et al., *The Effect of Glucosamine and/or Chondroitin Sulfate on the Progression of Knee Osteoarthritis: A GAIT Report*, 58(10) J. Arthritis Rheum. 3183–91 (Oct. 2008); Sawitzke, A.D., *Clinical Efficacy And Safety Of Glucosamine, Chondroitin Sulphate,*

⁵ To a similar effect, a study by Kwok, et al., entitled *The Joints On Glucosamine (JOG) Study: A Randomized, Double-Blind, Placebo-Controlled Trial To Assess The Structural Benefit Of Glucosamine In Knee Osteoarthritis Based On 3T MRI*, 60 Arthritis Rheum 725 (2009), concluded that glucosamine was not effective in preventing the worsening of cartilage damage.

Their Combination, Celecoxib Or Placebo Taken To Treat Osteoarthritis Of The Knee: 2-Year Results From GAIT, 69(8) Ann Rheum. Dis. 1459-64 (Aug. 2010).

24. The GAIT studies are consistent with the reported results of other studies that have demonstrated the ineffectiveness of both glucosamine and chondroitin.

- In 2008, a study concluded that glucosamine was no better than a placebo in reducing either the symptoms or progression of hip osteoarthritis. Rozendaal et al., *Effect of Glucosamine Sulfate on Hip Osteoarthritis*, 148 Ann. of Intern. Med. 268-77 (2008)

- A 2010 a meta-analysis examined prior studies involving glucosamine and chondroitin, alone or in combination, and reported that the collection of studies supported a conclusion that those compounds neither reduced joint pain nor had an impact on the narrowing of joint space. Wandel et al., *Effects of Glucosamine, Chondroitin, Or Placebo In Patients With Osteoarthritis Or Hip Or Knee: Network Meta-Analysis*, BMJ 341:c4675 (2010).

- Another 2010 study concluded that there was no difference between placebo and glucosamine for the treatment of low back pain and lumbar osteoarthritis and that there was no data recommending the use of glucosamine. Wilkens et al., *Effect of Glucosamine on Pain-Related Disability in Patients With Chronic Low Back Pain and Degenerative Lumbar Osteoarthritis*, 304(1) JAMA 45-52 (July 7, 2010).

- In 2011, a summary article reviewed the available literature and concluded that “[t]he cost-effectiveness of these dietary supplements alone or in combination in the treatment of OA has not been demonstrated in North America.” Miller, K. and Clegg, D., *Glucosamine and Chondroitin Sulfate*, Rheum. Dis. Clin. N. Am. 37 (2011) 103-118.

- Most recently, a meta-analysis synthesized all available studies evaluating the efficacy of glucosamine for treating osteoarthritis and concluded that glucosamine showed *no pain reduction benefits* for osteoarthritis. Wu D. et al., *Efficacies of different preparations of*

glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials, 67(6) Int. J. Clin. Pract. 585-94 (June 2013).

25. Scientific studies have also shown that the other ingredients in the Supplements are similarly ineffective. See, e.g., S. Brien, et. al., *Systematic Review Of The Nutritional Supplements (DMSO) And Methylsulfonylmethane (MSM) In The Treatment Of Osteoarthritis*, 16 *Osteoarthritis and Cartilage*, 1277 (Nov. 2008); Usha PR and Naidu MU, *Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonylmethane and their Combination in Osteoarthritis*, 24 *Clinical Drug Investigation* 353-63 (2004); see also Biegert C et al., *Efficacy and Safety of Willow Bark Extract in the Treatment of Osteoarthritis and Rheumatoid Arthritis: Results of 2 Randomized Double-Blind Controlled Trials*, *Journal of Rheumatology* 31.11 (2004): 2121-30 (no efficacy for willow bark as compared with placebo and willow bark less effective than low dosages of non-steroidal anti-inflammatory); see also Abdel-Tawb, M., et al., *Boswellia Serrata: An Overall Assessment Of In Vitro, Preclinical, Pharmacokinetic And Clinical Data*, 50 *Clin Pharmacokinet.* 349-69 (2011).

26. Rite Aid's claims that the Supplements "help rebuild cartilage" are also totally belied by the available scientific evidence:

- In October 2008, the GAIT Study also concluded that glucosamine and/or chondroitin, alone or in combination, did not demonstrate a clinically important difference in joint space loss, indicating that they were ineffective in rebuilding or regenerating cartilage. Sawitzke et al., *The Effect of Glucosamine and/or Chondroitin Sulfate on the Progression of Knee Osteoarthritis, A Report from the Glucosamine/Chondroitin Arthritis Intervention Trial*, 58 *Arthritis Rheum.* 3183-3191 (2008).

- In April 2009, the *Journal of Orthopaedic Surgery* published an article that concluded that there was scant evidence to support a claim that glucosamine was superior to

placebo in even arresting the deterioration of cartilage, to say nothing of arresting that process and promoting regeneration or rebuilding. Kirkham, et al., *Review Article: Glucosamine*, 17(1) Journal of Orthopaedic Surgery 72-6 (2009).

Rite Aid Harms Consumers By Continuing To Market And Sell the Supplements

27. Undeterred by the weight of scientific evidence demonstrating that the ingredients in the Supplements are wholly ineffective, Rite Aid conveyed and continues to convey one uniform message: the Supplements lubricate and comfort joints and promote growth of cartilage.

28. As the manufacturer and/or distributor of the Supplements, Rite Aid possesses specialized knowledge regarding the efficacy of the ingredients contained in its products and, moreover, is in a superior position to, and has, learned of the lack of efficacy for all of the key ingredients in the Supplements.

29. Specifically, Rite Aid knew, but failed to disclose, that the Supplements do not provide the joint health benefits represented and that well-conducted, clinical studies have found the ingredients in the Supplements to be ineffective in providing the joint health benefits claimed by Rite Aid.

30. Plaintiff and Class members have been and will continue to be deceived or misled by Defendant's deceptive joint health benefit representations. Plaintiff purchased and consumed one of the Supplements during the Class period and in doing so, read and considered the advertising and marketing by Rite Aid and based his decision to purchase the Products on the joint health benefit representations on the packaging and on Defendant's website. Rite Aid's joint health benefit representations and omissions were a material factor in influencing Plaintiff's decision to purchase and consume the product he purchased.

31. Other than obtaining the benefits that the Supplements promise but do not deliver, there is no other reason for Plaintiff and the Class to have purchased the Supplements as the

Supplements are not represented to provide any other benefits and Plaintiff and the Class would not have purchased the Supplements had they known Rite Aid's joint health benefit statements were false and misleading and that clinical cause and effect studies have found the ingredients to be ineffective for the represented joint health benefits.

32. As a result, Plaintiff and the Class members have been injured in fact in their purchases of the Supplements in that they were deceived into purchasing Products that do not perform as advertised.

33. Rite Aid, by contrast, reaped enormous profit from its false marketing and sale of the Supplements.

CLASS DEFINITION AND ALLEGATIONS

34. Plaintiff Lastres brings this action on behalf of himself and all other similarly situated persons pursuant to Rule 23(a), (b)(2), and (b)(3) of the Federal Rules of Civil Procedure and seeks certification of the following Class:

All consumers who, within the applicable statute of limitations period, purchased the Supplements within the State of New York.

Excluded from the Class are Rite Aid, its parents, subsidiaries, affiliates, officers and directors, and those who purchased the Supplements for resale.

35. The members of the Class are so numerous that joinder of all members of the Class is impracticable. Plaintiff is informed and believes that the proposed Class contains thousands of purchasers of the Supplements who have been damaged by Rite Aid's conduct as alleged herein. The precise number of Class members is unknown to Plaintiff.

36. This action involves common questions of law and fact, which predominate over any questions affecting individual Class members. These common legal and factual questions include, but are not limited to, the following:

- (1) whether the claims discussed above are true, or are misleading, or objectively reasonably likely to deceive;
- (2) whether Rite Aid's alleged conduct violates public policy;
- (3) whether the alleged conduct constitutes violations of the laws asserted;
- (4) whether Rite Aid engaged in false or misleading advertising;
- (5) whether Plaintiff and Class members have sustained monetary loss and the proper measure of that loss; and
- (6) whether Plaintiff and Class members are entitled to other appropriate remedies, including corrective advertising and injunctive relief.

37. Plaintiff's claims are typical of the claims of the members of the Class because, inter alia, all Class members were injured through the uniform misconduct described above having been exposed to Rite Aid's false representations regarding the efficacy of the Supplements. Plaintiff is advancing the same claims and legal theories on behalf of himself and all members of the Class.

38. Plaintiff will fairly and adequately protect the interests of the members of the Class, has retained counsel experienced in complex consumer class action litigation, and intends to prosecute this action vigorously. Plaintiff has no adverse or antagonistic interests to those of the Class.

39. A class action is superior to all other available means for the fair and efficient adjudication of this controversy. The damages or other financial detriment suffered by individual Class members is relatively small compared to the burden and expense that would be entailed by individual litigation of their claims against Rite Aid. It would thus be virtually impossible for the Class, on an individual basis, to obtain effective redress for the wrongs done to them. Individualized litigation would create the danger of inconsistent or contradictory

judgments arising from the same set of facts and would also increase the delay and expense to all parties and the courts. By contrast, the class action device provides the benefits of adjudication of these issues in a single proceeding, ensures economies of scale and comprehensive supervision by a single court, and presents no unusual management difficulties under the circumstances here.

40. Plaintiff seeks preliminary and permanent injunctive and equitable relief on behalf of the entire Class, preventing Rite Aid from further engaging in the acts described and requiring Rite Aid to provide full restitution to Plaintiff and Class members.

41. Unless a Class is certified, Rite Aid will retain monies received as a result of its conduct that were taken from Plaintiff and Class members. Unless a Class-wide injunction is issued, Rite Aid will continue to commit the violations alleged, and the members of the Class and the general public will continue to be deceived.

42. Rite Aid has acted and refused to act on grounds generally applicable to the Class, making appropriate final injunctive relief with respect to the Class as a whole.

COUNT I
New York Gen Bus. Law § 349
(New York Class)

43. Plaintiff repeats the allegations in the foregoing paragraphs as if fully set forth herein.

44. Plaintiff brings this Count on behalf of himself and the members of the Class against Defendant.

45. Representing that the Supplements help “rebuild cartilage” is deceptive, and has the capacity, tendency and effect of deceiving reasonable consumers who purchase the products.

Reasonable consumers would believe that the Supplements help rebuild cartilage, based upon Defendant's misrepresentations to that effect.

46. By the acts and conduct alleged herein, Defendant committed unfair or deceptive acts and practices by making the Misrepresentations.

47. The foregoing deceptive acts and practices were directed at consumers.

48. The foregoing deceptive acts and practices are misleading in a material way because they fundamentally misrepresent the characteristics and efficacy of the Supplements to induce consumers to purchase same.

49. Plaintiff and members of the Class were injured because they paid for the Supplements, which they would not have done had they known the truth about the Supplements.

50. On behalf of himself and other members of the Class, Plaintiff seeks to enjoin the unlawful acts and practices described herein, to recover his actual damages or fifty dollars, whichever is greater, three times actual damages, and reasonable attorneys' fees.

COUNT II
(False Advertising, New York Gen Bus. Law § 350)
(New York Class)

51. Plaintiff repeats the allegations in the foregoing paragraphs as if fully set forth herein.

52. Plaintiff brings this Count individually and on behalf of the members of the Class against Defendant.

53. Based on the foregoing, Defendant has engaged in consumer-oriented conduct that is deceptive or misleading in a material way which constitutes false advertising in violation of Section 350 of the New York General Business Law.

54. Defendant's false, misleading and deceptive statements and representations of fact, including but not limited to the Misrepresentations, were and are directed to consumers.

55. Defendant's false, misleading and deceptive statements and representations of fact, including but not limited to the Misrepresentations, were and are likely to mislead a reasonable consumer acting reasonably under the circumstances.

56. Defendant's false, misleading and deceptive statements and representations of fact, including but not limited to the Misrepresentations, have resulted in consumer injury or harm to the public interest.

57. As a result of Defendant's false, misleading and deceptive statements and representations of fact, including but not limited to the Misrepresentations, Plaintiff has suffered and continues to suffer economic injury.

58. Plaintiff and the Class members suffered an ascertainable loss caused by Defendant's misrepresentations because they paid for the Supplements, which they would not have done had they known the truth about the Supplements.

59. On behalf of himself and other members of the Class, Plaintiff seeks to enjoin the unlawful acts and practices described herein, to recover their actual damages or five hundred dollars, whichever is greater, three times actual damages, and reasonable attorneys' fees.

COUNT III
(Breach of Express Warranty, N.Y. U.C.C. § 2-313)
(New York Class)

60. Plaintiff repeats the allegations in the foregoing paragraphs as if fully set forth herein.

61. Plaintiff brings this Count individually and on behalf of the members of the Class against Defendant.

62. Defendant is and was at all relevant times a merchant under N.Y. U.C.C. § 2-313.

63. Defendant, as the manufacturer, marketer, distributor, and/or seller expressly warranted that the Supplements were fit for their intended purpose by making the Express Warranties described *supra* at ¶¶ 4, 15 and 19.

64. In fact, the Supplements are not fit for such purpose because each of the Express Warranties is false and misleading.

65. Plaintiff and the Class members were injured as a direct and proximate result of Defendant's breach because they would not have purchased the Supplements if they knew the truth about the product.

66. Defendant was provided notice of these issues by the letter sent by Fedex to Defendant on behalf of Plaintiff Louis Lastres in advance of the filing of this Complaint.

PRAYER FOR RELIEF

Wherefore, Plaintiff prays for a judgment:


- A. Certifying the Class as requested herein;
- B. Awarding Plaintiff and the proposed Class members damages;
- C. Awarding restitution and disgorgement of Rite Aid's revenues to Plaintiff and the proposed Class members;
- D. Awarding injunctive relief as permitted by law or equity, including enjoining Rite Aid from continuing the unlawful practices as set forth herein, and directing Rite Aid to identify, with Court supervision, victims of its conduct and pay them all money it is required to pay;
- E. Ordering Rite Aid to engage in a corrective advertising campaign;
- F. Awarding statutory and punitive damages, as appropriate;
- G. Awarding attorneys' fees and costs; and
- H. Providing such further relief as may be just and proper.

DEMAND FOR JURY TRIAL

Plaintiff hereby demands a trial of his claims by jury to the extent authorized by law.

Dated: November 22, 2013

Respectfully Submitted,



John D. Zaremba, Esq.

JDZ3958

ZAREMBA BROWNELL & BROWN

Robert Corbett, Esq.

RC5252

Of Counsel, Zaremba Brownell & Brown

40 Wall Street - 27th Floor

New York, NY 10005

Tel: (212) 380-6700

Fax: (212) 871-6395

jzaremba@zbbblaw.com

/s/ Benjamin J. Sweet

Benjamin J. Sweet

PA87338

Edwin J. Kilpela, Jr.

PA201595

DEL SOLE CAVANAUGH STROYD LLC

200 First Avenue, Suite 300

Pittsburgh, PA 15222

Tel: (412) 261-2393

Fax: (412) 261-2110

/s/ R. Bruce Carlson

R. Bruce Carlson

PA56657

Gary F. Lynch

PA56887

CARLSON LYNCH LTD

PNC Park

115 Federal Street, Suite 210

Pittsburgh, PA 15212

Tel: (412) 322-9243

Fax: (412) 231-0246

CIVIL COVER SHEET

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. (SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)

I. (a) PLAINTIFFS

Louis Lastres

(b) County of Residence of First Listed Plaintiff Kings County, NY
(EXCEPT IN U.S. PLAINTIFF CASES)

(c) Attorneys (Firm Name, Address, and Telephone Number)
ZAREMBA BROWNELL & BROWN PLLC
40 Wall Street, 27th Floor, New York, New York 10005
(212) 380-6700

DEFENDANTS

Rite Aid, Corporation

County of Residence of First Listed Defendant N/A
(IN U.S. PLAINTIFF CASES ONLY)

NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF
THE TRACT OF LAND INVOLVED.

Attorneys (If Known)

II. BASIS OF JURISDICTION (Place an "X" in One Box Only)

- ☐ 1 U.S. Government Plaintiff
- ☐ 2 U.S. Government Defendant
- ☐ 3 Federal Question
(U.S. Government Not a Party)
- ☒ 4 Diversity
(Indicate Citizenship of Parties in Item III)

III. CITIZENSHIP OF PRINCIPAL PARTIES (Place an "X" in One Box for Plaintiff and One Box for Defendant)

- | | PTF | DEF | | PTF | DEF |
|---|---------------------------------------|----------------------------|---|----------------------------|----------------------------|
| Citizen of This State | <input checked="" type="checkbox"/> 1 | <input type="checkbox"/> 1 | Incorporated or Principal Place of Business In This State | <input type="checkbox"/> 4 | <input type="checkbox"/> 4 |
| Citizen of Another State | <input type="checkbox"/> 2 | <input type="checkbox"/> 2 | Incorporated and Principal Place of Business In Another State | <input type="checkbox"/> 5 | <input type="checkbox"/> 5 |
| Citizen or Subject of a Foreign Country | <input type="checkbox"/> 3 | <input type="checkbox"/> 3 | Foreign Nation | <input type="checkbox"/> 6 | <input type="checkbox"/> 6 |

IV. NATURE OF SUIT (Place an "X" in One Box Only)

CONTRACT	TORTS	FORFEITURE/PENALTY	BANKRUPTCY	OTHER STATUTES
<input type="checkbox"/> 110 Insurance <input type="checkbox"/> 120 Marine <input type="checkbox"/> 130 Miller Act <input type="checkbox"/> 140 Negotiable Instrument <input type="checkbox"/> 150 Recovery of Overpayment & Enforcement of Judgment <input type="checkbox"/> 151 Medicare Act <input type="checkbox"/> 152 Recovery of Defaulted Student Loans (Excludes Veterans) <input type="checkbox"/> 153 Recovery of Overpayment of Veteran's Benefits <input type="checkbox"/> 160 Stockholders' Suits <input type="checkbox"/> 190 Other Contract <input type="checkbox"/> 195 Contract Product Liability <input type="checkbox"/> 196 Franchise	PERSONAL INJURY <input type="checkbox"/> 310 Airplane <input type="checkbox"/> 315 Airplane Product Liability <input type="checkbox"/> 320 Assault, Libel & Slander <input type="checkbox"/> 330 Federal Employers' Liability <input type="checkbox"/> 340 Marine <input type="checkbox"/> 345 Marine Product Liability <input type="checkbox"/> 350 Motor Vehicle <input type="checkbox"/> 355 Motor Vehicle Product Liability <input type="checkbox"/> 360 Other Personal Injury <input type="checkbox"/> 362 Personal Injury - Medical Malpractice PERSONAL INJURY <input checked="" type="checkbox"/> 365 Personal Injury - Product Liability <input type="checkbox"/> 367 Health Care/Pharmaceutical Personal Injury Product Liability <input type="checkbox"/> 368 Asbestos Personal Injury Product Liability PERSONAL PROPERTY <input type="checkbox"/> 370 Other Fraud <input type="checkbox"/> 371 Truth in Lending <input type="checkbox"/> 380 Other Personal Property Damage <input type="checkbox"/> 385 Property Damage Product Liability	<input type="checkbox"/> 625 Drug Related Seizure of Property 21 USC 881 <input type="checkbox"/> 690 Other LABOR <input type="checkbox"/> 710 Fair Labor Standards Act <input type="checkbox"/> 720 Labor/Management Relations <input type="checkbox"/> 740 Railway Labor Act <input type="checkbox"/> 751 Family and Medical Leave Act <input type="checkbox"/> 790 Other Labor Litigation <input type="checkbox"/> 791 Employee Retirement Income Security Act IMMIGRATION <input type="checkbox"/> 462 Naturalization Application <input type="checkbox"/> 465 Other Immigration Actions	<input type="checkbox"/> 422 Appeal 28 USC 158 <input type="checkbox"/> 423 Withdrawal 28 USC 157 PROPERTY RIGHTS <input type="checkbox"/> 820 Copyrights <input type="checkbox"/> 830 Patent <input type="checkbox"/> 840 Trademark SOCIAL SECURITY <input type="checkbox"/> 861 HIA (1395ff) <input type="checkbox"/> 862 Black Lung (923) <input type="checkbox"/> 863 DIWC/DIWW (405(g)) <input type="checkbox"/> 864 SSID Title XVI <input type="checkbox"/> 865 RSI (405(g)) FEDERAL TAX SUITS <input type="checkbox"/> 870 Taxes (U.S. Plaintiff or Defendant) <input type="checkbox"/> 871 IRS—Third Party 26 USC 7609	<input type="checkbox"/> 375 False Claims Act <input type="checkbox"/> 400 State Reapportionment <input type="checkbox"/> 410 Antitrust <input type="checkbox"/> 430 Banks and Banking <input type="checkbox"/> 450 Commerce <input type="checkbox"/> 460 Deportation <input type="checkbox"/> 470 Racketeer Influenced and Corrupt Organizations <input type="checkbox"/> 480 Consumer Credit <input type="checkbox"/> 490 Cable/Sat TV <input type="checkbox"/> 850 Securities/Commodities/Exchange <input type="checkbox"/> 890 Other Statutory Actions <input type="checkbox"/> 891 Agricultural Acts <input type="checkbox"/> 893 Environmental Matters <input type="checkbox"/> 895 Freedom of Information Act <input type="checkbox"/> 896 Arbitration <input type="checkbox"/> 899 Administrative Procedure Act/Review or Appeal of Agency Decision <input type="checkbox"/> 950 Constitutionality of State Statutes
REAL PROPERTY <input type="checkbox"/> 210 Land Condemnation <input type="checkbox"/> 220 Foreclosure <input type="checkbox"/> 230 Rent Lease & Ejectment <input type="checkbox"/> 240 Torts to Land <input type="checkbox"/> 245 Tort Product Liability <input type="checkbox"/> 290 All Other Real Property	CIVIL RIGHTS <input type="checkbox"/> 440 Other Civil Rights <input type="checkbox"/> 441 Voting <input type="checkbox"/> 442 Employment <input type="checkbox"/> 443 Housing/Accommodations <input type="checkbox"/> 445 Amer. w/Disabilities - Employment <input type="checkbox"/> 446 Amer. w/Disabilities - Other <input type="checkbox"/> 448 Education PRISONER PETITIONS Habeas Corpus: <input type="checkbox"/> 463 Alien Detainee <input type="checkbox"/> 510 Motions to Vacate Sentence <input type="checkbox"/> 530 General <input type="checkbox"/> 535 Death Penalty Other: <input type="checkbox"/> 540 Mandamus & Other <input type="checkbox"/> 550 Civil Rights <input type="checkbox"/> 555 Prison Condition <input type="checkbox"/> 560 Civil Detainee - Conditions of Confinement			

V. ORIGIN (Place an "X" in One Box Only)

- ☒ 1 Original Proceeding
- ☐ 2 Removed from State Court
- ☐ 3 Remanded from Appellate Court
- ☐ 4 Reinstated or Reopened
- ☐ 5 Transferred from Another District (specify)
- ☐ 6 Multidistrict Litigation

VI. CAUSE OF ACTION

Cite the U.S. Civil Statute under which you are filing (Do not cite jurisdictional statutes unless diversity):

28 U.S.C. §§ 1332

Brief description of cause:

Products liability

VII. REQUESTED IN COMPLAINT:

☐ CHECK IF THIS IS A CLASS ACTION UNDER RULE 23, F.R.Cv.P.

DEMAND \$

CHECK YES only if demanded in complaint:

JURY DEMAND: ☒ Yes ☐ No

VIII. RELATED CASE(S) IF ANY

(See instructions):

JUDGE

DOCKET NUMBER

DATE

11/25/2013

SIGNATURE OF ATTORNEY OF RECORD

/s/John D. Zaremba (JDZ3958)

FOR OFFICE USE ONLY

RECEIPT #

AMOUNT

APPLYING IFP

JUDGE

MAG. JUDGE

Local Arbitration Rule 83.10 provides that with certain exceptions, actions seeking money damages only in an amount not in excess of \$150,000, exclusive of interest and costs, are eligible for compulsory arbitration. The amount of damages is presumed to be below the threshold amount unless a certification to the contrary is filed.

I, John Zaremba, counsel for LOUIS LASTRES, do hereby certify that the above captioned civil action is ineligible for compulsory arbitration for the following reason(s):

- ☒ monetary damages sought are in excess of \$150,000, exclusive of interest and costs,
- ☒ the complaint seeks injunctive relief,
- ☐ the matter is otherwise ineligible for the following reason

DISCLOSURE STATEMENT - FEDERAL RULES CIVIL PROCEDURE 7.1

Identify any parent corporation and any publicly held corporation that owns 10% or more of its stocks:

RELATED CASE STATEMENT (Section VIII on the Front of this Form)

Please list all cases that are arguably related pursuant to Division of Business Rule 50.3.1 in Section VIII on the front of this form. Rule 50.3.1 (a) provides that "A civil case is "related" to another civil case for purposes of this guideline when, because of the similarity of facts and legal issues or because the cases arise from the same transactions or events, a substantial saving of judicial resources is likely to result from assigning both cases to the same judge and magistrate judge." Rule 50.3.1 (b) provides that "A civil case shall not be deemed "related" to another civil case merely because the civil case: (A) involves identical legal issues, or (B) involves the same parties." Rule 50.3.1 (c) further provides that "Presumptively, and subject to the power of a judge to determine otherwise pursuant to paragraph (d), civil cases shall not be deemed to be "related" unless both cases are still pending before the court."

NY-E DIVISION OF BUSINESS RULE 50.1(d)(2)

- 1.) Is the civil action being filed in the Eastern District removed from a New York State Court located in Nassau or Suffolk County? No
- 2.) If you answered "no" above:
- a) Did the events or omissions giving rise to the claim or claims, or a substantial part thereof, occur in Nassau or Suffolk County? No
- b) Did the events of omissions giving rise to the claim or claims, or a substantial part thereof, occur in the Eastern District? No

If your answer to question 2 (b) is "No," does the defendant (or a majority of the defendants, if there is more than one) reside in Nassau or Suffolk County, or, in an interpleader action, does the claimant (or a majority of the claimants, if there is more than one) reside in Nassau or Suffolk County? No

(Note: A corporation shall be considered a resident of the County in which it has the most significant contacts).

BAR ADMISSION

I am currently admitted in the Eastern District of New York and currently a member in good standing of the bar of this court.

☒ Yes ☐ No

Are you currently the subject of any disciplinary action (s) in this or any other state or federal court?

☐ Yes (If yes, please explain) ☒ No

I certify the accuracy of all information provided above.

Signature: /s/John D. Zaremba (JDZ3958)